[go: up one dir, main page]

ATE544463T1 - Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen - Google Patents

Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Info

Publication number
ATE544463T1
ATE544463T1 AT05851326T AT05851326T ATE544463T1 AT E544463 T1 ATE544463 T1 AT E544463T1 AT 05851326 T AT05851326 T AT 05851326T AT 05851326 T AT05851326 T AT 05851326T AT E544463 T1 ATE544463 T1 AT E544463T1
Authority
AT
Austria
Prior art keywords
scf
treatment
polypeptide
brain
combination
Prior art date
Application number
AT05851326T
Other languages
English (en)
Inventor
Li-Ru Zhao
John Kessler
Seema Singhal
Mehta Jayesh
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Application granted granted Critical
Publication of ATE544463T1 publication Critical patent/ATE544463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05851326T 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen ATE544463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62518904P 2004-11-05 2004-11-05
PCT/US2005/039792 WO2006055260A2 (en) 2004-11-05 2005-11-04 Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders

Publications (1)

Publication Number Publication Date
ATE544463T1 true ATE544463T1 (de) 2012-02-15

Family

ID=36407603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851326T ATE544463T1 (de) 2004-11-05 2005-11-04 Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen

Country Status (6)

Country Link
US (2) US20060153799A1 (de)
EP (1) EP1817047B1 (de)
AT (1) ATE544463T1 (de)
AU (1) AU2005306894B2 (de)
CA (1) CA2586365A1 (de)
WO (1) WO2006055260A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629775A1 (en) 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
DE102006004142A1 (de) * 2006-01-27 2007-08-02 Axaron Bioscience Ag Neue therapeutische Indikationen von Koloniestimulierenden Faktoren
US9770485B2 (en) * 2006-02-21 2017-09-26 Academia Sinica Methods for rescuing learning and/or memory deficits caused by alzheimer's disease by G-CSF
US7618938B2 (en) * 2007-02-07 2009-11-17 Academia Sinica Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
RU2011108560A (ru) 2008-08-05 2012-09-10 Юниверсити Оф Саут Флорида (Us) Способы лечения когнитивного нарушения
KR20100020125A (ko) * 2008-08-12 2010-02-22 한양대학교 산학협력단 Ｇ-ｃｓｆ를 유효성분으로 하는 신경병증성 통증 예방 또는치료제
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
AU2012289433B2 (en) 2011-07-25 2017-07-27 Evive Biotechnology (Shanghai) Ltd Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
CN107260760B (zh) 2013-02-06 2021-08-31 Nc医学研究公司 用于治疗神经变性的细胞疗法
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
US10039808B2 (en) 2014-10-22 2018-08-07 Michael Chez Method of treating or improving neurological function in a human subject
US9925244B1 (en) 2015-02-17 2018-03-27 Michael Chez Treatment of warts in non-immunosuppressed patients
WO2019200240A1 (en) 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Transmembrane stem cell factor (tm-scf) lipid nanocarriers and methods of use thereof
WO2023158681A1 (en) * 2022-02-16 2023-08-24 Vasogenesis Inc. Methods of using a blood cell growth factor to treat impaired blood flow

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
WO1988001297A1 (en) 1986-08-11 1988-02-25 Cetus Corporation Expression of g-csf and muteins thereof
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
DK174044B1 (da) 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
NZ229098A (en) 1988-05-13 1992-10-28 Amgen Inc (bg-csf) bovine granulocyte colony stimulating factor, recombinant methods and pharmaceuticals
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE464482C (sv) 1989-08-25 1997-09-08 Teknoskand Invent Ab Med spärr försett svängarmsbeslag till fönster, luckor o d
WO1991005798A1 (en) * 1989-10-10 1991-05-02 Amgen Inc. Compositions and methods for treating or preventing infections in canine and feline animals
US6248319B1 (en) * 1989-10-16 2001-06-19 Krisztina M. Zsebo Method for increasing hematopoietic progenitor cells by stem cell factor polypeptides
EP0676470A1 (de) * 1989-10-16 1995-10-11 Amgen Inc. Stammzellenfaktor
US6204363B1 (en) * 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
WO1991005795A1 (en) 1989-10-16 1991-05-02 Amgen Inc. Stem cell factor
US6207454B1 (en) * 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
JPH04164098A (ja) 1990-03-07 1992-06-09 Kirin Amgen Inc 化学修飾顆粒球コロニー刺激因子誘導体
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5241072A (en) 1990-05-25 1993-08-31 Genzyne Corporation Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof
EP0536317A1 (de) 1990-06-25 1993-04-14 Immunex Corporation Wachstumsfaktor der mastzellen
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
WO1992004455A1 (en) 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
WO1992006116A1 (en) 1990-09-28 1992-04-16 Ortho Pharmaceutical Corporation Hybrid growth factors
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
EP0601043B1 (de) 1991-08-30 1998-11-25 Fred Hutchinson Cancer Research Center Hybride cytokine
FR2686900B1 (fr) 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
PT726778E (pt) 1994-02-08 2001-12-28 Amgen Inc Sistema de administracao oral de proteinas g-csf modificadas quimicamente
US5525708A (en) 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
JP4891477B2 (ja) 1997-10-02 2012-03-07 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． 血管新生及び／または既存細動脈網から側枝動脈及び／または他の動脈の発達の調節に関する方法
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE10033219A1 (de) * 2000-07-07 2002-01-24 Univ Heidelberg Neuroprotektive Wirkung von Granulocyten-Colony Stimmulierendem Faktor (G-CSF)
MXPA04000231A (es) 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
AU2002332041A1 (en) 2001-10-05 2003-04-22 Human Genome Sciences, Inc. Albumin fusion proteins
US7605128B2 (en) * 2002-02-14 2009-10-20 Buck Institute For Age Research Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia
AU2003268484A1 (en) * 2002-09-06 2004-03-29 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors

Also Published As

Publication number Publication date
CA2586365A1 (en) 2006-05-26
WO2006055260A3 (en) 2006-07-27
US20100286039A1 (en) 2010-11-11
US20060153799A1 (en) 2006-07-13
AU2005306894B2 (en) 2011-11-24
AU2005306894A1 (en) 2006-05-26
WO2006055260A2 (en) 2006-05-26
EP1817047A2 (de) 2007-08-15
US8524655B2 (en) 2013-09-03
EP1817047B1 (de) 2012-02-08

Similar Documents

Publication Publication Date Title
ATE544463T1 (de) Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
WO2008097861A3 (en) MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS
ATE521608T1 (de) Glucokinaseaktivatoren
EP2377530A3 (de) Modulation von Neurogenese durch PDE-Hemmung
WO2006105359A3 (en) Methods for stimulating hair growth by administering bmps
ATE545422T1 (de) Beta-glycolipide als immunomodulatoren
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
EA201270591A1 (ru) ДВУЗАМЕЩЕННЫЕ ОКТАГИДРОПИРРОЛ[3,4-c]ПИРРОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРЕКСИНОВЫХ РЕЦЕПТОРОВ
WO2008021196A3 (en) Methods and compositions for the treatment of medical disorders
WO2008083204A3 (en) Modulation of neurogenesis by melatoninergic ligands
MX2007004551A (es) Compuestos tiadiazol y metodos de uso.
WO2009106991A3 (en) Pyridazine derivatives and their use as therapeutic agents in the treatment of skin disorders
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
EP2698166A3 (de) Komplementhemmung für verbesserte Nervenregeneration
DE60329756D1 (de) Mitotische kinesin-hemmer
WO2005113590A3 (en) Bmp10 propeptides and related methods
SI1771474T1 (sl) Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
TW200744629A (en) Treatments for neurological disorders
WO2007040565A3 (en) Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
DK2714888T3 (da) Rekombinant gær
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
DK1709161T3 (da) Humane terapeutiske celler, som udskiller nervevækstfaktor
ATE433966T1 (de) Methylendipiperidinderivate
ATE484291T1 (de) Behandlung von neurologischen störungen mit hämatopoetischen wachstumsfaktoren